Loading…
← CockpitCompetitor Analysis › 600530.SS Shanghai Jiaoda Onlly Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Jiaoda Onlly Co., Ltd. Class A600530.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 100
Mkt cap
$726M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$4.74M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.0 pp
WACC 5.0%
Hurdle
+44 pp
Req g minus delivered
Close · CNYCN¥5.91
1D+8.6%
1W+25.5%
1M+64.2%
3M+54.3%
6M-25.2%
YTD-8.2%
1Y-30.5%
ATR %4.6%
52w lowhigh31.5% off high

What Shanghai Jiaoda Onlly does

Employees: 939

Shanghai Jiaoda Onlly at a glance

Size Shanghai Jiaoda Onlly (600530.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $726M, the 2814th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.91 on 18 Nov 2026.

Performance Over six months the shares fell 25.2%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 2.3% over the last twelve months (peer median +3.2%); the operating margin is -2.2% (peer median 9.7%).

Valuation It trades at 16.1× enterprise value to sales against a peer median of 2.4× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.0 points above its cost of capital (5.0% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 94600530.SS 79
Six months, rebased to 100: Shanghai Jiaoda Onlly against the median of its 20 peers (local-currency closes).

Shanghai Jiaoda Onlly financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥305MCN¥313MCN¥324MCN¥295MCN¥376M
Revenue growth—-3%+10%-21%—
Gross profitCN¥125MCN¥88.6MCN¥92.6MCN¥65.5MCN¥145M
EBITDAn/aCN¥57.2MCN¥69.3MCN¥30.3M-CN¥287M
Net income-CN¥16.9MCN¥3.49MCN¥30.5M-CN¥35.1M-CN¥499M
Free cash flowCN¥37.2MCN¥20.1MCN¥58.2MCN¥46.1MCN¥72.5M
Capital expenditureCN¥3.50MCN¥2.94MCN¥5.48MCN¥9.55MCN¥25.8M
Total debtCN¥155MCN¥160MCN¥158MCN¥209MCN¥277M

Quarterly statements and history in the cockpit →

Shanghai Jiaoda Onlly competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+25%+50%688566688799SGMT6039982186057045346004792171002907002424NVCT3001LXRX4985000915002390BLISSGVS600530.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Jiaoda Onlly is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×68856668879960399821860570453421710029070024243001LXRX000915002390BLISSGVS600530.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Jiaoda Onlly is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688566603998218630070560047900290760082900242430014985002390BLISSGVS600530.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Jiaoda Onlly is the large dot.

Shanghai Jiaoda Onlly competitors and peer comparison

How Shanghai Jiaoda Onlly compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Jiaoda Onlly against its 20 peers (data as of 18 Nov 2026)
Measure600530.SSPeer medianRank in peer set
1-month return+64.2%-4.1%highest of 21
6-month return-25.2%-7.0%6th lowest of 21
Distance from 52-week high-31.5%-34.0%10th highest of 21
Revenue growth (TTM)-2.3%+3.2%8th lowest of 19
Operating margin-2.2%9.7%3rd lowest of 19
EV / Sales16.1×2.4×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)42.7%-0.7%most demanding of 13
Growth delivered (Del g)-0.9%+1.2%3rd lowest of 13
Hurdle (Req g minus delivered)+43.7 pp-1.7 ppmost demanding of 13
ROIC minus cost of capital+0.0 pp+0.5 pp8th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%

Questions

Which companies are Shanghai Jiaoda Onlly's closest peers?
The cockpit's peer set: Jiangsu Jibeier Pharmaceutical (688566.SS), Hunan Warrant Pharmaceutical (688799.SS), Sagimet Biosciences (SGMT), Hunan Fangsheng Pharmaceutical (603998.SS), Luye Pharma (2186.HK), China Traditional Chinese Medicine (0570.HK), Hunan Jiudian Pharmaceutical (300705.SZ), Mochida Pharmaceutical (4534.T).
Is Shanghai Jiaoda Onlly expensive compared with its peers?
On ev / sales it trades at 16.1× against a peer median of 2.4×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shanghai Jiaoda Onlly stock performed?
Over six months to 18 Nov 2026 the shares returned -25.2% against -7.0% for the median peer; over one year -30.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.